Tags : Liver Fibrosis

Biotech

Takeda Signs a License Agreement with Genevant to Develop Novel

Shots: Genevant to receive up to $600M up front and milestone as well as royalties on future product sales Takeda get exclusive rights to access Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets The companies collaborated to discover, develop and commercialize the LNP-delivered nucleic acid therapeutics directed to previously inaccessible […]Read More

M&A

Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Shots: Genentech to acquire Jecure, in all stock transaction for the portfolio of preclinical NLRP3 inhibitors The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis NLRP3 – Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein3, investigated for the treatment of autoimmune and […]Read More